DCGI approves market authorisation for SII’s Covid vaccine Covovax as heterologous booster dose
New Delhi: The Drug Controller General of India (DCGI) has approved market authorisation to COVID-19 vaccine Covovax as a heterologous ...
Read moreNew Delhi: The Drug Controller General of India (DCGI) has approved market authorisation to COVID-19 vaccine Covovax as a heterologous ...
Read moreNew Delhi: A day after its Covid shot ‘Covovax’ was included on the CoWIN portal for inoculation of children aged ...
Read moreNew Delhi: The COVID-19 Working Group of the NTAGI has recommended inclusion of the Serum Institute's Covovax in the national ...
Read moreNew Delhi: The Drugs Controller General of India (DCGI) granted permission on Wednesday for conducting the phase-3 clinical trial of ...
Read moreNew Delhi: Serum Institute of India (SII) has urged the Union government to include Covovax in the National Covid-19 vaccination ...
Read moreNew Delhi: Serum Institute of India (SII) has sought emergency use authorisation (EUA) from DGCI for its Covid-19 vaccine ‘Covovax’ ...
Read moreNew Delhi: Expanding India’s vaccine basket, the Central Drug Authority has approved the Serum Institute of India’s Covid-19 vaccine ‘Covovax’, ...
Read moreNew Delhi: Serum Institute of India (SII) plans to launch a Covid-19 vaccine for children in the next six months. ...
Read moreNew Delhi: Serum Institute of India (SII) CEO Adar Poonawalla Saturday said clinical trials of COVID-19 vaccine Covovax have begun in ...
Read more